“Functional Equivalence” For 2004: Aranesp OPPS Payment Is 78% Of AWP
Executive Summary
Medicare will reimburse Amgen's Aranesp at about 78% of AWP under a revised Hospital Outpatient Prospective Payment System rule
You may also be interested in...
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22